Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
Report Scope
This report incorporates an in-depth analysis of CAR T-cell therapy’s current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players’ profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies’ business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.
Report Includes
This report incorporates an in-depth analysis of CAR T-cell therapy’s current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players’ profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies’ business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.
Report Includes
- 14 data tables and 71 additional tables
- Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D
- Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region
- Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors
- Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
- Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along with a look into the patent expirations in the industry
- An analysis of patents, emerging trends and developments in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca
CHAPTER 1 EXECUTIVE SUMMARY
Market Outlook
Scope of Report
Market Summary
CHAPTER 2 MARKET OVERVIEW
Overview
Market and Technology Background
A Brief History of CAR T-Cell Therapy
FDA Product Approvals
Other CAR T-Cell Therapies
Clinical Applications of CAR T-Cell Therapy
Adoptive Cell Transfer (ACT) Technologies
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Increasing Incidence of Cancer
Growing Investments and Funding in CAR T-Cell Therapy Research
Robust R&D Pipeline
Advances in Genetic Engineering
Market Restraints
Complex Legislative and Regulatory Procedures
Alternative Products from Competitors
Market Opportunities
Growing Significance of Precision Medicine
Expanding Applications for CAR T-Cell Therapy
Market Challenges
Complex Manufacturing and Supply Chain
Reimbursement Challenges for CAR T-Cell Therapy
CHAPTER 4 EMERGING TECHNOLOGIES AND CLINICAL TRIALS
Introduction
Clinical Trials Being Conducted Globally
Distribution of CAR T-Cell Clinical Trials in China
CHAPTER 5 MARKET SEGMENTATION ANALYSIS
Key Takeaways
Segmentation Breakdown
Global Market for CAR T-Cell Therapy, by Product
Yescarta
Kymriah
Tecartus
Abecma
Breyanzi
Carvykti
Global Market for CAR T-Cell Therapy, by Indication
Geographic Breakdown
Global Market for CAR T-Cell Therapy, by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 6 PATENT REVIEW AND NEW DEVELOPMENTS
Introduction
Anticipated Increase in Patent Litigation on Customized Patient Treatments
Company-specific Intellectual Property and Patent Information
Amgen
Avacta Life Sciences Ltd.
Bluebird Bio
Celgene Corp.
Cellectis
Celyad SA
Editas Medicine Inc.
Eureka Therapeutics Inc.
iCell Gene Therapeutics
Juno Therapeutics Inc. (A Celgene Co.)
Noile-Immune Biotech
Novartis AG
CHAPTER 7 COMPETITIVE INTELLIGENCE
Ranking of Leading Players
Strategic Considerations
CHAPTER 8 SUSTAINABILITY IN THE CAR T-CELL THERAPY MARKET: ESG PERSPECTIVE
Introduction to ESG
Role of ESG in the Pharma Industry
ESG Performance Analysis
Environmental
Social
Governance
ESG Risk Ratings
Conclusion
CHAPTER 9 APPENDIX
Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
ALLOGENE THERAPEUTICS
AMGEN INC.
ASTRAZENECA
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
ICELL GENE THERAPEUTICS INC.
JOHNSON & JOHNSON SERVICES INC.
LES LABORATOIRES SERVIER
NOVARTIS AG
PFIZER INC.
PROTHERAGEN INC.
Market Outlook
Scope of Report
Market Summary
CHAPTER 2 MARKET OVERVIEW
Overview
Market and Technology Background
A Brief History of CAR T-Cell Therapy
FDA Product Approvals
Other CAR T-Cell Therapies
Clinical Applications of CAR T-Cell Therapy
Adoptive Cell Transfer (ACT) Technologies
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Increasing Incidence of Cancer
Growing Investments and Funding in CAR T-Cell Therapy Research
Robust R&D Pipeline
Advances in Genetic Engineering
Market Restraints
Complex Legislative and Regulatory Procedures
Alternative Products from Competitors
Market Opportunities
Growing Significance of Precision Medicine
Expanding Applications for CAR T-Cell Therapy
Market Challenges
Complex Manufacturing and Supply Chain
Reimbursement Challenges for CAR T-Cell Therapy
CHAPTER 4 EMERGING TECHNOLOGIES AND CLINICAL TRIALS
Introduction
Clinical Trials Being Conducted Globally
Distribution of CAR T-Cell Clinical Trials in China
CHAPTER 5 MARKET SEGMENTATION ANALYSIS
Key Takeaways
Segmentation Breakdown
Global Market for CAR T-Cell Therapy, by Product
Yescarta
Kymriah
Tecartus
Abecma
Breyanzi
Carvykti
Global Market for CAR T-Cell Therapy, by Indication
Geographic Breakdown
Global Market for CAR T-Cell Therapy, by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 6 PATENT REVIEW AND NEW DEVELOPMENTS
Introduction
Anticipated Increase in Patent Litigation on Customized Patient Treatments
Company-specific Intellectual Property and Patent Information
Amgen
Avacta Life Sciences Ltd.
Bluebird Bio
Celgene Corp.
Cellectis
Celyad SA
Editas Medicine Inc.
Eureka Therapeutics Inc.
iCell Gene Therapeutics
Juno Therapeutics Inc. (A Celgene Co.)
Noile-Immune Biotech
Novartis AG
CHAPTER 7 COMPETITIVE INTELLIGENCE
Ranking of Leading Players
Strategic Considerations
CHAPTER 8 SUSTAINABILITY IN THE CAR T-CELL THERAPY MARKET: ESG PERSPECTIVE
Introduction to ESG
Role of ESG in the Pharma Industry
ESG Performance Analysis
Environmental
Social
Governance
ESG Risk Ratings
Conclusion
CHAPTER 9 APPENDIX
Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
ALLOGENE THERAPEUTICS
AMGEN INC.
ASTRAZENECA
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
ICELL GENE THERAPEUTICS INC.
JOHNSON & JOHNSON SERVICES INC.
LES LABORATOIRES SERVIER
NOVARTIS AG
PFIZER INC.
PROTHERAGEN INC.
LIST OF TABLES
Summary Table : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 1 : U.S. FDA-approved CAR T-cell Therapies, 2017–2022
Table 2 : Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues
Table 3 : Tumor-Associated Antigens of CAR T-Cell Targets
Table 4 : Global Cancer Statistics, 2022
Table 5 : Clinical Trials of CAR T-Cell Therapy, by Select Countries, January 2023
Table 6 : CAR T-Cell Therapy Clinical Trials Distribution, by Investigators and Collaborators, January 2023
Table 7 : Emerging CAR T-Cell Therapy Clinical Trials, by Company
Table 8 : Clinical Trials on CD19 Directed CAR T Cells in the U.S.
Table 9 : Examples of Clinical Trials on CD19-Directed CAR T Cells in China
Table 10 : Examples of Clinical Trials on CAR T Cells Targeting Non-CD19 Antigens in China
Table 11 : Examples of Clinical Trials on CAR T Cells for Solid Tumors in China
Table 12 : Clinical Trials on CAR T Cells with Fourth-Generation CARs in China
Table 13 : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 14 : Global Market for CAR T-Cell Therapy, by Indication, Through 2029
Table 15 : Clinical Trials of CAR T-cell Therapy in Other Indications
Table 16 : Global Market for CAR T-Cell Therapy, by Region, Through 2029
Table 17 : Bluebird Bio: Patents and Patent Applications, 2012–2021
Table 18 : Celgene Corp.: Patents and Patent Applications, 2018–2021
Table 19 : Cellectis: Patents and Patent Applications, 2018–2021
Table 20 : Editas Medicine: Patent Applications, 2015–2021
Table 21 : Eureka Therapeutics: Patent Applications, 2012–2021
Table 22 : iCell Gene Therapeutics: Patent Applications, 2017–2019
Table 23 : Juno Therapeutics Inc. and Memorial Sloan Kettering Cancer Center: Patents and Patent Applications, 2000–2021
Table 24 : Noile-Immune Biotech Inc. Yamaguchi University Patent Applications, 2017
Table 25 : Novartis AG and University of Pennsylvania: Patents and Patent Applications, 2013–2021
Table 26 : Leading Companies in the CAR T-Cell Therapy Market, 2023
Table 27 : Focus Areas in ESG Metrics
Table 28 : ESG Risk Rankings for CAR T-Cell Therapy Companies, 2024*
Table 29 : Abbreviations Used in this Report
Table 30 : AbbVie Inc.: Company Snapshot
Table 31 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 32 : AbbVie Inc.: Product Portfolio
Table 33 : AbbVie Inc.: News/Key Developments, 2023–2024
Table 34 : Allogene Therapeutics: Company Snapshot
Table 35 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
Table 36 : Allogene Therapeutics: Product Portfolio
Table 37 : Allogene Therapeutics: News/Key Developments, 2024
Table 38 : Amgen Inc.: Company Snapshot
Table 39 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 40 : Amgen Inc.: Product Portfolio
Table 41 : Amgen Inc.: News/Key Developments, 2024
Table 42 : AstraZeneca: Company Snapshot
Table 43 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 44 : AstraZeneca: Product Portfolio
Table 45 : AstraZeneca: News/Key Developments, 2023–2024
Table 46 : Bluebird Bio Inc.: Company Snapshot
Table 47 : Bluebird Bio Inc.: Financial Performance, FY 2022 and 2023
Table 48 : Bluebird Bio Inc.: Product Portfolio
Table 49 : Bluebird Bio Inc.: News/Key Developments, 2020-2022
Table 50 : Bristol-Myers Squibb Co.: Company Snapshot
Table 51 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 52 : Bristol-Myers Squibb Co.: Product Portfolio
Table 53 : Bristol-Myers Squibb Co.: News/Key Developments, 2023–2024
Table 54 : Cellectis S.A.: Company Snapshot
Table 55 : Cellectis S.A.: Financial Performance, FY 2022 and 2023
Table 56 : Cellectis S.A.: Product Portfolio
Table 57 : Cellectis S.A.: News/Key Developments, 2023–2024
Table 58 : Eureka Therapeutics Inc.: Company Snapshot
Table 59 : Eureka Therapeutics Inc: Product Portfolio
Table 60 : Eureka Therapeutics Inc.: News/Key Developments, 2023–2024
Table 61 : Gilead Sciences Inc.: Company Snapshot
Table 62 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 63 : Gilead Sciences Inc.: Product Portfolio
Table 64 : Gilead Sciences Inc.: News/Key Developments, 2022–2024
Table 65 : iCell Gene Therapeutics Inc.: Company Snapshot
Table 66 : iCell Gene Therapeutics Inc: Product Portfolio
Table 67 : iCell Gene Therapeutics Inc.: News/Key Developments, 2024
Table 68 : Johnson & Johnson Services Inc.: Company Snapshot
Table 69 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 70 : Johnson & Johnson Services Inc.: Product Portfolio
Table 71 : Johnson & Johnson Services Inc.: News/Key Developments, 2022–2024
Table 72 : Les Laboratoires Servier: Company Snapshot
Table 73 : Les Laboratoires Servier: Product Portfolio
Table 74 : Les Laboratoires Servier: News/Key Developments, 2024
Table 75 : Novartis AG: Company Snapshot
Table 76 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 77 : Novartis AG: Product Portfolio
Table 78 : Novartis AG: News/Key Developments, 2021–2024
Table 79 : Pfizer Inc.: Company Snapshot
Table 80 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 81 : Pfizer Inc.: Product Portfolio
Table 82 : Pfizer Inc.: News/Key Developments, 2023
Table 83 : Protheragen Inc.: Company Snapshot
Table 84 : Protheragen Inc.: Product Portfolio
Summary Table : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 1 : U.S. FDA-approved CAR T-cell Therapies, 2017–2022
Table 2 : Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues
Table 3 : Tumor-Associated Antigens of CAR T-Cell Targets
Table 4 : Global Cancer Statistics, 2022
Table 5 : Clinical Trials of CAR T-Cell Therapy, by Select Countries, January 2023
Table 6 : CAR T-Cell Therapy Clinical Trials Distribution, by Investigators and Collaborators, January 2023
Table 7 : Emerging CAR T-Cell Therapy Clinical Trials, by Company
Table 8 : Clinical Trials on CD19 Directed CAR T Cells in the U.S.
Table 9 : Examples of Clinical Trials on CD19-Directed CAR T Cells in China
Table 10 : Examples of Clinical Trials on CAR T Cells Targeting Non-CD19 Antigens in China
Table 11 : Examples of Clinical Trials on CAR T Cells for Solid Tumors in China
Table 12 : Clinical Trials on CAR T Cells with Fourth-Generation CARs in China
Table 13 : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 14 : Global Market for CAR T-Cell Therapy, by Indication, Through 2029
Table 15 : Clinical Trials of CAR T-cell Therapy in Other Indications
Table 16 : Global Market for CAR T-Cell Therapy, by Region, Through 2029
Table 17 : Bluebird Bio: Patents and Patent Applications, 2012–2021
Table 18 : Celgene Corp.: Patents and Patent Applications, 2018–2021
Table 19 : Cellectis: Patents and Patent Applications, 2018–2021
Table 20 : Editas Medicine: Patent Applications, 2015–2021
Table 21 : Eureka Therapeutics: Patent Applications, 2012–2021
Table 22 : iCell Gene Therapeutics: Patent Applications, 2017–2019
Table 23 : Juno Therapeutics Inc. and Memorial Sloan Kettering Cancer Center: Patents and Patent Applications, 2000–2021
Table 24 : Noile-Immune Biotech Inc. Yamaguchi University Patent Applications, 2017
Table 25 : Novartis AG and University of Pennsylvania: Patents and Patent Applications, 2013–2021
Table 26 : Leading Companies in the CAR T-Cell Therapy Market, 2023
Table 27 : Focus Areas in ESG Metrics
Table 28 : ESG Risk Rankings for CAR T-Cell Therapy Companies, 2024*
Table 29 : Abbreviations Used in this Report
Table 30 : AbbVie Inc.: Company Snapshot
Table 31 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 32 : AbbVie Inc.: Product Portfolio
Table 33 : AbbVie Inc.: News/Key Developments, 2023–2024
Table 34 : Allogene Therapeutics: Company Snapshot
Table 35 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
Table 36 : Allogene Therapeutics: Product Portfolio
Table 37 : Allogene Therapeutics: News/Key Developments, 2024
Table 38 : Amgen Inc.: Company Snapshot
Table 39 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 40 : Amgen Inc.: Product Portfolio
Table 41 : Amgen Inc.: News/Key Developments, 2024
Table 42 : AstraZeneca: Company Snapshot
Table 43 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 44 : AstraZeneca: Product Portfolio
Table 45 : AstraZeneca: News/Key Developments, 2023–2024
Table 46 : Bluebird Bio Inc.: Company Snapshot
Table 47 : Bluebird Bio Inc.: Financial Performance, FY 2022 and 2023
Table 48 : Bluebird Bio Inc.: Product Portfolio
Table 49 : Bluebird Bio Inc.: News/Key Developments, 2020-2022
Table 50 : Bristol-Myers Squibb Co.: Company Snapshot
Table 51 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 52 : Bristol-Myers Squibb Co.: Product Portfolio
Table 53 : Bristol-Myers Squibb Co.: News/Key Developments, 2023–2024
Table 54 : Cellectis S.A.: Company Snapshot
Table 55 : Cellectis S.A.: Financial Performance, FY 2022 and 2023
Table 56 : Cellectis S.A.: Product Portfolio
Table 57 : Cellectis S.A.: News/Key Developments, 2023–2024
Table 58 : Eureka Therapeutics Inc.: Company Snapshot
Table 59 : Eureka Therapeutics Inc: Product Portfolio
Table 60 : Eureka Therapeutics Inc.: News/Key Developments, 2023–2024
Table 61 : Gilead Sciences Inc.: Company Snapshot
Table 62 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 63 : Gilead Sciences Inc.: Product Portfolio
Table 64 : Gilead Sciences Inc.: News/Key Developments, 2022–2024
Table 65 : iCell Gene Therapeutics Inc.: Company Snapshot
Table 66 : iCell Gene Therapeutics Inc: Product Portfolio
Table 67 : iCell Gene Therapeutics Inc.: News/Key Developments, 2024
Table 68 : Johnson & Johnson Services Inc.: Company Snapshot
Table 69 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 70 : Johnson & Johnson Services Inc.: Product Portfolio
Table 71 : Johnson & Johnson Services Inc.: News/Key Developments, 2022–2024
Table 72 : Les Laboratoires Servier: Company Snapshot
Table 73 : Les Laboratoires Servier: Product Portfolio
Table 74 : Les Laboratoires Servier: News/Key Developments, 2024
Table 75 : Novartis AG: Company Snapshot
Table 76 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 77 : Novartis AG: Product Portfolio
Table 78 : Novartis AG: News/Key Developments, 2021–2024
Table 79 : Pfizer Inc.: Company Snapshot
Table 80 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 81 : Pfizer Inc.: Product Portfolio
Table 82 : Pfizer Inc.: News/Key Developments, 2023
Table 83 : Protheragen Inc.: Company Snapshot
Table 84 : Protheragen Inc.: Product Portfolio
